Study Summary
This trial is testing if a 68Gallium PSMA PET/CT scan can better detect cancer in people with metastatic bladder cancer than the standard FDG-PET/CT scan.
Eligible Conditions
- Bladder Cancer
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: 1 year
1 year
Define the proportion of patients with 1 or more lesions detectable by 68Gallium PSMA-PET/CT
Trial Safety
Safety Progress
Trial Design
1 Treatment Group
68Gallium PSMA-PET/CT
1 of 1
Experimental Treatment
10 Total Participants · 1 Treatment Group
Primary Treatment: 68Gallium PSMA-PET/CT · No Placebo Group · Phase 1
68Gallium PSMA-PET/CTExperimental Group · 2 Interventions: PET/CT imaging, [68Ga]PSMA · Intervention Types: DiagnosticTest, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET/CT imaging
2016
Completed Phase 3
~410
Trial Logistics
Trial Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 year
Who is running the clinical trial?
Memorial Sloan Kettering Cancer CenterLead Sponsor
1,832 Previous Clinical Trials
584,528 Total Patients Enrolled
Gopakumar IyerPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
Eligibility Criteria
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Patient must be able to understand and is willing to sign a written informed consent document.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Conditions
Cancer Related
Treatments